Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
 
Sign in
Join now
Published in COVID-19 and
1 other channel

Journal Scan / Research · September 03, 2022

Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2

JAMA Network Open

 

 Save  Recommend
 Share

Additional Info

JAMA Network Open
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial
JAMA Netw Open 2022 Aug 15;5(8)e2225411, C Portal-Celhay, E Forleo-Neto, W Eagan, BJ Musser, JD Davis, KC Turner, T Norton, AT Hooper, JD Hamilton, C Pan, A Mahmood, A Baum, CA Kyratsous, Y Kim, J Parrino, W Kampman, L Roque-Guerrero, R Stoici, A Fatakia, Y Soo, GP Geba, B Kowal, AT DiCioccio, N Stahl, L Lipsich, N Braunstein, GA Herman, GD Yancopoulos, DM Weinreich

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated